Latest Oncology News

NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis

NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis

June 3rd 2025

Caroline Seymour

The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.

Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma

Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma

June 3rd 2025

Kyle Doherty

Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.

Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma

Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma

June 3rd 2025

Ashley Chan

Adjuvant encorafenib/binimetinib was well tolerated with a manageable toxicity profile in patients with high-risk, stage IIB/C BRAF V600-mutant melanoma.

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma

June 3rd 2025

Ariana Pelosci

Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

June 3rd 2025

Ashley Chan

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

Latest Oncology Videos

Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC
Looking Ahead For the Treatments of R/R MM
Dr Preeshagul on Emerging Treatments in SCLC
Expert Perspectives: Standardizing HER2 Testing in Gynecological Cancer
Novel Treatment Approaches Under Investigation in ROS1+ NSCLC
ASCO 2025: Top Data Highlights from 6/3
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Clinical Perspectives: 59yF with R/R CLL Experiencing BTKi Treatment-Related AE
Expert Perspectives: Sequencing Strategies after Acalabrutinib + Venetoclax +/- Obinutuzumab as First-Line Therapy in CLL
ASCO 2025: Top Data Highlights from 6/2
Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression
Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer
Dr Olawaiye on Data for Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Dr Duska on the Role of Immunotherapy With Definitive Treatment in High-Risk, Locally Advanced Cervical Cancer
Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer
Dr Sammons on the Efficacy of RLY-2608 Plus Fulvestrant in PIK3CA-Mutant HR+/HER2– Breast Cancer
Dr Kuykendall on Clinical Benefit With Rusfertide in Phlebotomy-Dependent Polycythemia Vera
ASCO 2025: Top Data Highlights from 6/1
Dr Char on the Association Between the Empirical Dietary Inflammatory Pattern and Survival Outcomes in Stage III Colon Cancer
Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA, Molecularly Higher-Risk NSCLC
ASCO 2025: Top Data Highlights from 5/31
Dr Powles on EFS With Sasanlimab Plus BCG in BCG-Naive, High-Risk NMIBC
Dr Matrana on the Persisting Need For Validated Biomarkers to Guide Treatment Selection in RCC

All Oncology News

One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel

June 3rd 2025

Gina Mauro

A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.

Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma

June 3rd 2025

Tim Cortese

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.

Olaparib Plus Radium-223 Generates Superior rPFS in CRPC

June 3rd 2025

Tony Berberabe

Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.

Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer

June 3rd 2025

Chris Ryan

Perioperative IMNN-001 plus chemotherapy generated numerical survival improvements in newly diagnosed epithelial ovarian cancer.

Brentuximab Vedotin Plus Chemo Wins EU Approval for Newly Diagnosed, Stage IIB-IV Hodgkin Lymphoma

June 3rd 2025

Ashling Wahner

Brentuximab vedotin plus ECADD chemotherapy has been approved in Europe for adult patients with newly diagnosed, stage IIB to IV Hodgkin lymphoma.

CAN-2409 Plus EBRT Bests EBRT Alone in High-Risk Localized Prostate Cancer

June 3rd 2025

Roman Fabbricatore

CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.

Adjuvant Nivolumab Plus Relatlimab Misses the Mark in Resected Stage III to IV Melanoma

June 3rd 2025

Kristi Rosa

Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025

Ashling Wahner

The FDA has approved darolutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer

June 3rd 2025

Sabrina Serani

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

June 3rd 2025

Russ Conroy

Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.

Ziftomenib Yields Complete Responses Regardless of Prior Therapy in NMP1-Mutant AML

June 3rd 2025

Ashling Wahner

Ziftomenib monotherapy elicited clinically meaningful, MRD-negative responses, including CRs, in heavily pretreated, relapsed/refractory NPM1-mutant AML.

NCCN Adds 2 Tests to CRC Screening Guidelines

June 3rd 2025

Chris Ryan

The NCCN has added the Shield blood test and the ColoSense test to its colorectal cancer screening guidelines.

CHMP Shares Positive Opinion for Denosumab Biosimilars for Osteoporosis and Skeletal-Related Cancer Complications

June 3rd 2025

Ashling Wahner

The European Medicines Agency's CHMP has recommended the use of denosumab biosimilars referencing Prolia and Xgeva in all reference product indications.

Consolidation Benmelstobart ± Anlotinib Provides Substantial PFS Benefits in Stage III NSCLC

June 3rd 2025

Jordyn Sava

Benmelstobart with or without anlotinib boosted progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

Neoadjuvant Nivolumab Plus Chemo Significantly Improves OS Vs Chemo in Resectable NSCLC

June 3rd 2025

Kristi Rosa

Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.

See All News